Denali Therapeutics Financial Ratios
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.45+0.78 (+4.18%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Denali Therapeutics ratio analysis
Return on equity reached -50.6%, meaning Denali Therapeutics generated -0.51 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Denali Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | — | 132.95 | — | — | — | — |
| Price / sales | — | — | 8.92 | 32.19 | 111.38 | 27.19 | 57.88 | 14.56 | — | — |
| Price / book | 2.77 | 2.84 | 2.86 | 3.35 | 5.63 | 7.93 | 3.91 | 3.44 | 0.50 | — |
| Operating margin | — | — | -59.5% | -314.2% | -607.8% | 18.7% | -799.1% | -35.9% | — | — |
| Net margin | — | — | -43.9% | -300.6% | -597.2% | 21.2% | -740.7% | -28.1% | — | — |
| Free cash flow margin | — | — | -112.2% | -242.1% | -451.9% | 123.1% | -635.3% | 36.2% | — | — |
| Return on equity (ROE) | -50.6% | -34.4% | -14.1% | -31.3% | -30.2% | 6.2% | -50.0% | -6.6% | -18.9% | — |
| Return on assets (ROA) | -44.8% | -30.8% | -12.6% | -22.3% | -20.7% | 4.4% | -35.7% | -5.5% | -18.1% | — |
| Current ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 | 9.48 | 14.67 | 28.92 | — |
| Revenue growth | — | -100.0% | 204.7% | 122.9% | -85.5% | 1,158.2% | -79.3% | — | — | — |
| EPS growth | — | — | — | — | -479.4% | — | — | — | — | — |